


IMU Biosciences collaborates with Waters to advance breakthrough AI immune mapping platform

June 26, 2026 | News

IMU's AI platform unlocks unprecedented immune insights for cancer and other diseases



US-based Waters Corporation and IMU Biosciences, a UK-based biotechnology startup, have announced a strategic partnership to accelerate the development of IMU's next-generation AI-powered High Definition (HD) Immunology platform.

The partnership brings together Waters Biosciences' advanced flow cytometry and single-cell technologies, including BD FACSDiscover Cell Analyzers, BD flow cytometry reagents with BD Horizon™ Real Dyes, BD Rhapsody Instruments, and BD OMICS-One™ WTA Next Assay and Protein Panels, with IMU's HD analysis and proprietary AI and machine learning analytics, that can reproducibly characterise the immune system in real time, to turn complex immune data into insights at scale across discovery, translational, and clinical research applications.

IMU measures the immune system in unprecedented detail, delivering more than 100 million data points from a single blood sample, combining HD multiomic analysis with machine learning analytics. IMU is building the world's largest immune dataset, with unrivaled access to patient samples and population-wide clinical data, establishing a universal standard for immune profiling.

The companies intend to pursue additional studies in translational research for novel biomarker discovery to enable clinical applications in flow cytometry.